Mycophenolate mofetil and neurological diseases

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Immune-mediated neurological disorders represent a significant clinical challenge.
• Existing treatments may have limitations or side effects.
• Mycophenolate mofetil (MMF) is an immunosuppressant with potential applications in neurology.

Purpose of the Study:

• To review the current experience and preliminary findings of using mycophenolate mofetil (MMF) in various neurological diseases.
• To assess the tolerability and potential efficacy of MMF in immune-mediated neurological conditions.

Main Methods:

• Review of case reports and small patient series.
• Analysis of open-label surveillance trials and Phase II studies.
• Evaluation of MMF as monotherapy and adjuvant therapy.

Main Results:

• MMF is generally well-tolerated in patients with neurological diseases.
• Preliminary data suggest MMF may be beneficial in polymyositis, chronic inflammatory demyelinating polyradiculoneuropathy, and multifocal motor neuropathy.
• MMF shows promise in multiple sclerosis treatment, potentially reducing steroid or IVIg requirements.

Conclusions:

• Mycophenolate mofetil (MMF) is a promising therapeutic option for select immune-mediated neurological disorders.
• Further well-designed clinical trials are needed to confirm efficacy, particularly in multiple sclerosis.
• MMF's favorable tolerability profile makes it an attractive alternative or adjunct therapy.